Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Peptides at the blood brain barrier: Knowing me knowing you.

Davis TP, Abbruscato TJ, Egleton RD.

Peptides. 2015 Oct;72:50-6. doi: 10.1016/j.peptides.2015.04.020. Epub 2015 Apr 30. Review.

2.

Drug abuse and the neurovascular unit.

Egleton RD, Abbruscato T.

Adv Pharmacol. 2014;71:451-80. doi: 10.1016/bs.apha.2014.06.019. Epub 2014 Aug 22. Review.

PMID:
25307226
3.

A paradigm shift for evaluating pharmacotherapy for Alzheimer's disease: the 10-patient screening protocol.

Weinstein JD, Gonzalez ER, Egleton RD, Hunt DA.

Consult Pharm. 2013 Jul;28(7):443-54. doi: 10.4140/TCP.n.2013.443. Review.

PMID:
23835462
4.

MG624, an α7-nAChR antagonist, inhibits angiogenesis via the Egr-1/FGF2 pathway.

Brown KC, Lau JK, Dom AM, Witte TR, Luo H, Crabtree CM, Shah YH, Shiflett BS, Marcelo AJ, Proper NA, Hardman WE, Egleton RD, Chen YC, Mangiarua EI, Dasgupta P.

Angiogenesis. 2012 Mar;15(1):99-114. doi: 10.1007/s10456-011-9246-9. Epub 2011 Dec 25. Erratum in: Angiogenesis. 2012 Jun;15(2):331. Dosage error in article text.

PMID:
22198237
5.

The α7-nicotinic acetylcholine receptor and MMP-2/-9 pathway mediate the proangiogenic effect of nicotine in human retinal endothelial cells.

Dom AM, Buckley AW, Brown KC, Egleton RD, Marcelo AJ, Proper NA, Weller DE, Shah YH, Lau JK, Dasgupta P.

Invest Ophthalmol Vis Sci. 2011 Jun 22;52(7):4428-38. doi: 10.1167/iovs.10-5461.

6.

Angiogenic activity of nicotinic acetylcholine receptors: implications in tobacco-related vascular diseases.

Egleton RD, Brown KC, Dasgupta P.

Pharmacol Ther. 2009 Feb;121(2):205-23. doi: 10.1016/j.pharmthera.2008.10.007. Epub 2008 Nov 14. Review.

PMID:
19063919
7.

Nociceptive inhibition prevents inflammatory pain induced changes in the blood-brain barrier.

Campos CR, Ocheltree SM, Hom S, Egleton RD, Davis TP.

Brain Res. 2008 Jul 24;1221:6-13. doi: 10.1016/j.brainres.2008.05.013. Epub 2008 May 17.

8.

Nicotinic acetylcholine receptors in cancer: multiple roles in proliferation and inhibition of apoptosis.

Egleton RD, Brown KC, Dasgupta P.

Trends Pharmacol Sci. 2008 Mar;29(3):151-8. doi: 10.1016/j.tips.2007.12.006. Epub 2008 Feb 11. Review.

PMID:
18262664
9.

Pathophysiology of the blood-brain barrier: animal models and methods.

Hawkins BT, Egleton RD.

Curr Top Dev Biol. 2008;80:277-309. Review.

PMID:
17950377
10.

Tight junctions contain oligomeric protein assembly critical for maintaining blood-brain barrier integrity in vivo.

McCaffrey G, Staatz WD, Quigley CA, Nametz N, Seelbach MJ, Campos CR, Brooks TA, Egleton RD, Davis TP.

J Neurochem. 2007 Dec;103(6):2540-55. doi: 10.1111/j.1471-4159.2007.04943.x.

11.

Peripheral inflammatory hyperalgesia modulates morphine delivery to the brain: a role for P-glycoprotein.

Seelbach MJ, Brooks TA, Egleton RD, Davis TP.

J Neurochem. 2007 Sep;102(5):1677-1690. doi: 10.1111/j.1471-4159.2007.04644.x.

12.

Comparative changes in the blood-brain barrier and cerebral infarction of SHR and WKY rats.

Hom S, Fleegal MA, Egleton RD, Campos CR, Hawkins BT, Davis TP.

Am J Physiol Regul Integr Comp Physiol. 2007 May;292(5):R1881-92. Epub 2007 Jan 18.

13.

Increased blood-brain barrier permeability and altered tight junctions in experimental diabetes in the rat: contribution of hyperglycaemia and matrix metalloproteinases.

Hawkins BT, Lundeen TF, Norwood KM, Brooks HL, Egleton RD.

Diabetologia. 2007 Jan;50(1):202-11. Epub 2006 Dec 2.

PMID:
17143608
14.

Decreased blood-brain barrier permeability to fluorescein in streptozotocin-treated rats.

Hawkins BT, Ocheltree SM, Norwood KM, Egleton RD.

Neurosci Lett. 2007 Jan 3;411(1):1-5. Epub 2006 Nov 15.

15.

Biphasic cytoarchitecture and functional changes in the BBB induced by chronic inflammatory pain.

Brooks TA, Ocheltree SM, Seelbach MJ, Charles RA, Nametz N, Egleton RD, Davis TP.

Brain Res. 2006 Nov 20;1120(1):172-82. Epub 2006 Sep 27.

16.

Fluorescence imaging of blood-brain barrier disruption.

Hawkins BT, Egleton RD.

J Neurosci Methods. 2006 Mar 15;151(2):262-7. Epub 2005 Sep 21.

PMID:
16181683
17.

Glycopeptides related to beta-endorphin adopt helical amphipathic conformations in the presence of lipid bilayers.

Dhanasekaran M, Palian MM, Alves I, Yeomans L, Keyari CM, Davis P, Bilsky EJ, Egleton RD, Yamamura HI, Jacobsen NE, Tollin G, Hruby VJ, Porreca F, Polt R.

J Am Chem Soc. 2005 Apr 20;127(15):5435-48.

PMID:
15826181
18.

Chronic inflammatory pain leads to increased blood-brain barrier permeability and tight junction protein alterations.

Brooks TA, Hawkins BT, Huber JD, Egleton RD, Davis TP.

Am J Physiol Heart Circ Physiol. 2005 Aug;289(2):H738-43. Epub 2005 Mar 25.

19.

Development of neuropeptide drugs that cross the blood-brain barrier.

Egleton RD, Davis TP.

NeuroRx. 2005 Jan;2(1):44-53. Review.

20.

Modulation of cerebral microvascular permeability by endothelial nicotinic acetylcholine receptors.

Hawkins BT, Egleton RD, Davis TP.

Am J Physiol Heart Circ Physiol. 2005 Jul;289(1):H212-9. Epub 2005 Feb 11.

21.

Nicotine increases in vivo blood-brain barrier permeability and alters cerebral microvascular tight junction protein distribution.

Hawkins BT, Abbruscato TJ, Egleton RD, Brown RC, Huber JD, Campos CR, Davis TP.

Brain Res. 2004 Nov 19;1027(1-2):48-58.

PMID:
15494156
22.
23.

Antinociceptive structure-activity studies with enkephalin-based opioid glycopeptides.

Elmagbari NO, Egleton RD, Palian MM, Lowery JJ, Schmid WR, Davis P, Navratilova E, Dhanasekaran M, Keyari CM, Yamamura HI, Porreca F, Hruby VJ, Polt R, Bilsky EJ.

J Pharmacol Exp Ther. 2004 Oct;311(1):290-7. Epub 2004 May 27.

PMID:
15166257
24.

Protection against hypoxia-induced blood-brain barrier disruption: changes in intracellular calcium.

Brown RC, Mark KS, Egleton RD, Davis TP.

Am J Physiol Cell Physiol. 2004 May;286(5):C1045-52. Epub 2003 Dec 18.

25.

Conjugation of low molecular weight poly(ethylene glycol) to biphalin enhances antinociceptive profile.

Huber JD, Campos CR, Egleton RD, Witt K, Guo L, Roberts MJ, Bentley MD, Davis TP.

J Pharm Sci. 2003 Jul;92(7):1377-85.

PMID:
12820142
26.

Differential effects of diabetes on rat choroid plexus ion transporter expression.

Egleton RD, Campos CC, Huber JD, Brown RC, Davis TP.

Diabetes. 2003 Jun;52(6):1496-501.

27.

Protection against hypoxia-induced increase in blood-brain barrier permeability: role of tight junction proteins and NFkappaB.

Brown RC, Mark KS, Egleton RD, Huber JD, Burroughs AR, Davis TP.

J Cell Sci. 2003 Feb 15;116(Pt 4):693-700.

28.

Pluronic p85 block copolymer enhances opioid peptide analgesia.

Witt KA, Huber JD, Egleton RD, Davis TP.

J Pharmacol Exp Ther. 2002 Nov;303(2):760-7.

PMID:
12388663
29.

Blood-brain barrier tight junctions are altered during a 72-h exposure to lambda-carrageenan-induced inflammatory pain.

Huber JD, Hau VS, Borg L, Campos CR, Egleton RD, Davis TP.

Am J Physiol Heart Circ Physiol. 2002 Oct;283(4):H1531-7. Epub 2002 Jun 13.

30.

Peptide drug modifications to enhance bioavailability and blood-brain barrier permeability.

Witt KA, Gillespie TJ, Huber JD, Egleton RD, Davis TP.

Peptides. 2001 Dec;22(12):2329-43. Review.

PMID:
11786210
31.

Molecular physiology and pathophysiology of tight junctions in the blood-brain barrier.

Huber JD, Egleton RD, Davis TP.

Trends Neurosci. 2001 Dec;24(12):719-25. Review.

PMID:
11718877
32.

Improved blood-brain barrier penetration and enhanced analgesia of an opioid peptide by glycosylation.

Egleton RD, Mitchell SA, Huber JD, Palian MM, Polt R, Davis TP.

J Pharmacol Exp Ther. 2001 Dec;299(3):967-72.

PMID:
11714884
33.

Pharmacodynamic and pharmacokinetic characterization of poly(ethylene glycol) conjugation to met-enkephalin analog [D-Pen2, D-Pen5]-enkephalin (DPDPE).

Witt KA, Huber JD, Egleton RD, Roberts MJ, Bentley MD, Guo L, Wei H, Yamamura HI, Davis TP.

J Pharmacol Exp Ther. 2001 Aug;298(2):848-56.

PMID:
11454951
34.

Inflammatory pain alters blood-brain barrier permeability and tight junctional protein expression.

Huber JD, Witt KA, Hom S, Egleton RD, Mark KS, Davis TP.

Am J Physiol Heart Circ Physiol. 2001 Mar;280(3):H1241-8.

35.

Effect of reduced flow on blood-brain barrier transport systems.

Hom S, Egleton RD, Huber JD, Davis TP.

Brain Res. 2001 Jan 26;890(1):38-48.

PMID:
11164767
36.

Insulin enhancement of opioid peptide transport across the blood-brain barrier and assessment of analgesic effect.

Witt KA, Huber JD, Egleton RD, Davis TP.

J Pharmacol Exp Ther. 2000 Dec;295(3):972-8.

PMID:
11082431
37.

Improved bioavailability to the brain of glycosylated Met-enkephalin analogs.

Egleton RD, Mitchell SA, Huber JD, Janders J, Stropova D, Polt R, Yamamura HI, Hruby VJ, Davis TP.

Brain Res. 2000 Oct 20;881(1):37-46.

PMID:
11033091
38.

Enkephalin glycopeptide analogues produce analgesia with reduced dependence liability.

Bilsky EJ, Egleton RD, Mitchell SA, Palian MM, Davis P, Huber JD, Jones H, Yamamura HI, Janders J, Davis TP, Porreca F, Hruby VJ, Polt R.

J Med Chem. 2000 Jun 29;43(13):2586-90.

PMID:
10891118
39.

Assessment of stereoselectivity of trimethylphenylalanine analogues of delta-opioid [D-Pen(2),D-Pen(5)]-enkephalin.

Witt KA, Slate CA, Egleton RD, Huber JD, Yamamura HI, Hruby VJ, Davis TP.

J Neurochem. 2000 Jul;75(1):424-35.

40.

The effect of halogenation on blood-brain barrier permeability of a novel peptide drug.

Gentry CL, Egleton RD, Gillespie T, Abbruscato TJ, Bechowski HB, Hruby VJ, Davis TP.

Peptides. 1999;20(10):1229-38.

PMID:
10573295
42.

Transport of opioid peptides into the central nervous system.

Egleton RD, Abbruscato TJ, Thomas SA, Davis TP.

J Pharm Sci. 1998 Nov;87(11):1433-9.

PMID:
9811502
43.

Bioavailability and transport of peptides and peptide drugs into the brain.

Egleton RD, Davis TP.

Peptides. 1997;18(9):1431-9. Review.

PMID:
9392847

Supplemental Content

Loading ...
Support Center